Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Oral Lactobacillus Crispatus Lc-G22 as Adjunctive Therapy to Clotrimazole for Preventing Recurrence of Vulvovaginal Candidiasis: A Single-Center, Randomized, Single-Blind, Placebo-Controlled Trial

NCT07727967 is registered in ClinicalTrials.gov with BioGrowing Co., Ltd as lead sponsor.

NCT NCT07727967
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07727967 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Oral Lactobacillus Crispatus Lc-G22 as Adjunctive Therapy to Clotrimazole for Preventing Recurrence of Vulvovaginal Candidiasis: A Single-Center, Randomized, Single-Blind, Placebo-Controlled Trial
Lead sponsor
BioGrowing Co., Ltd
Phase
Not applicable
Overall status
Completed
Start date
July 1, 2022
Completion date
October 31, 2024
Enrollment
100 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

vulvovaginal candidiasis